MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592517 | Name: Esomeprazole
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Esomeprazole is an inhibitor of the gastric H+/K+-ATPase and the (S) enantiomer of omeprazole. It reversibly inhibits the activity of the H+/K+-ATPase in an enzyme assay. Esomeprazole (30 mg/kg, s.c.) inhibits histamine-induced gastric acid secretion in rats. Formulations containing esomeprazole in complex with magnesium have been used as proton pump inhibitors (PPIs) in the treatment of gastroesophageal reflux disease (GERD), H. pylori eradication, and hypersecretory conditions, as well as in the prevention of non-steroidal anti-inflammatory disease-related gastric ulcer.

Chemical Structure

Esomeprazole
Esomeprazole
CAS#119141-88-7 (free base)

Theoretical Analysis

MedKoo Cat#: 592517

Name: Esomeprazole

CAS#: 119141-88-7 (free base)

Chemical Formula: C17H19N3O3S

Exact Mass: 345.1100

Molecular Weight: 345.42

Elemental Analysis: C, 59.11; H, 5.54; N, 12.17; O, 13.90; S, 9.28

Price and Availability

Size Price Availability Quantity
100mg USD 250.00 2 Weeks
250mg USD 450.00 2 Weeks
500mg USD 750.00 2 Weeks
1g USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
161796-78-7 (sodium) 119141-88-7 (free base) 161973-10-0 (magnesium) 217087-09-7 (magnesium hydrate) 161796-84-5 (potassium) 914613-86-8 (strontium) 934714-36-0 (strontium hydrate)
Synonym
Esomeprazole; (–)-Omeprazole; (–) Omeprazole; (S)-Omeprazole; (S) Omeprazole; Inexium paranova; (S)-(-)-Omeprazole; (S)-Esomeprazole
IUPAC/Chemical Name
1H-Benzimidazole, 5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-
InChi Key
SUBDBMMJDZJVOS-DEOSSOPVSA-N
InChi Code
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1
SMILES Code
O=[S@](C1=NC2=CC(OC)=CC=C2N1)CC3=NC=C(C)C(OC)=C3C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
An H+/K+-ATPase inhibitor.
In vitro activity:
This study found that the expression of both DDAH and iNOS were significantly downregulated by esomeprazole (Fig. 1). For example, the gene expression of iNOS was increased by about 100-fold upon induction with bleomycin, and treatment with esomeprazole decreased the induction in iNOS expression by about 25-fold (Fig. 1). Reference: J Inflamm (Lond). 2021; 18: 17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136131/
In vivo activity:
The administration of esomeprazole in different doses significantly reduced the MDA levels in the HE+WIR group (P=0.0001<0.001) and the LE+WIR group (P=0.0001<0.001) (Figure 4A; Table 3). Compared with the NS group, the level of GSH in the WIR group was declined (P=0.012<0.05), which was rescued by the high-dose esomeprazole treatment (P=0.036<0.05) (Figure 4B; Table 3). The assessment revealed that the WIR treatment significantly reduced the levels of SOD relative to that of the NS group (P=0.025<0.05), and this condition was reversed by the prophylactic administration of the high-dose esomeprazole (P=0.048<0.05) (Figure 4C; Table 3). The rats in the HE group did not show any significant changes in the levels of MDA (P=0.963), GSH (P=0.980), SOD (P=0.875) and SOD1 (P=0.809) in the stomach tissue compared with the NS group rats (Figure 4A–D). Reference: Drug Des Devel Ther. 2019; 13: 2969–2984. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709796/
Solvent mg/mL mM
Solubility
DMF 30.0 86.85
DMSO 20.0 57.90
Ethanol 10.0 28.95
PBS (pH 7.2) 10.0 28.95
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 345.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Ebrahimpour A, Wang M, Li L, Jegga AG, Bonnen MD, Eissa NT, Raghu G, Jyothula S, Kheradmand F, Hanania NA, Rosas IO, Ghebre YT. Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. J Inflamm (Lond). 2021 May 19;18(1):17. doi: 10.1186/s12950-021-00284-6. PMID: 34011367; PMCID: PMC8136131. 2. Xu Q, Jia X, Wu Q, Shi L, Ma Z, Ba N, Zhao H, Xia X, Zhang Z. Esomeprazole affects the proliferation, metastasis, apoptosis and chemosensitivity of gastric cancer cells by regulating lncRNA/circRNA-miRNA-mRNA ceRNA networks. Oncol Lett. 2020 Dec;20(6):329. doi: 10.3892/ol.2020.12193. Epub 2020 Oct 6. PMID: 33101498; PMCID: PMC7577076. 3. Xie W, Huang X, Chen R, Chen R, Li T, Wu W, Huang Z. Esomeprazole alleviates the damage to stress ulcer in rats through not only its antisecretory effect but its antioxidant effect by inactivating the p38 MAPK and NF-κB signaling pathways. Drug Des Devel Ther. 2019 Aug 22;13:2969-2984. doi: 10.2147/DDDT.S193641. PMID: 31686780; PMCID: PMC6709796. 4. Pham N, Ludwig MS, Wang M, Ebrahimpour A, Bonnen MD, Diwan AH, Kim SJ, Bryan J, Newton JM, Sikora AG, Donovan DT, Sandulache V, Ghebre YT. Topical Esomeprazole Mitigates Radiation-Induced Dermal Inflammation and Fibrosis. Radiat Res. 2019 Nov;192(5):473-482. doi: 10.1667/RR15398.1. Epub 2019 Aug 15. PMID: 31415221; PMCID: PMC6876297.
In vitro protocol:
1. Ebrahimpour A, Wang M, Li L, Jegga AG, Bonnen MD, Eissa NT, Raghu G, Jyothula S, Kheradmand F, Hanania NA, Rosas IO, Ghebre YT. Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. J Inflamm (Lond). 2021 May 19;18(1):17. doi: 10.1186/s12950-021-00284-6. PMID: 34011367; PMCID: PMC8136131. 2. Xu Q, Jia X, Wu Q, Shi L, Ma Z, Ba N, Zhao H, Xia X, Zhang Z. Esomeprazole affects the proliferation, metastasis, apoptosis and chemosensitivity of gastric cancer cells by regulating lncRNA/circRNA-miRNA-mRNA ceRNA networks. Oncol Lett. 2020 Dec;20(6):329. doi: 10.3892/ol.2020.12193. Epub 2020 Oct 6. PMID: 33101498; PMCID: PMC7577076.
In vivo protocol:
1. Xie W, Huang X, Chen R, Chen R, Li T, Wu W, Huang Z. Esomeprazole alleviates the damage to stress ulcer in rats through not only its antisecretory effect but its antioxidant effect by inactivating the p38 MAPK and NF-κB signaling pathways. Drug Des Devel Ther. 2019 Aug 22;13:2969-2984. doi: 10.2147/DDDT.S193641. PMID: 31686780; PMCID: PMC6709796. 2. Pham N, Ludwig MS, Wang M, Ebrahimpour A, Bonnen MD, Diwan AH, Kim SJ, Bryan J, Newton JM, Sikora AG, Donovan DT, Sandulache V, Ghebre YT. Topical Esomeprazole Mitigates Radiation-Induced Dermal Inflammation and Fibrosis. Radiat Res. 2019 Nov;192(5):473-482. doi: 10.1667/RR15398.1. Epub 2019 Aug 15. PMID: 31415221; PMCID: PMC6876297.
1: Papp LA, Hancu G, Kelemen H, Tóth G. Chiral separation in the class of proton pump inhibitors by chromatographic and electromigration techniques: An overview. Electrophoresis. 2021 May 18. doi: 10.1002/elps.202100032. Epub ahead of print. PMID: 34004039. 2: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Esomeprazole. 2021 Mar 17. PMID: 30000343. 3: Abrignani MG, Gatta L, Gabrielli D, Milazzo G, De Francesco V, De Luca L, Francese M, Imazio M, Riccio E, Rossini R, Scotto di Uccio F, Soncini M, Zullo A, Colivicchi F, Di Lenarda A, Gulizia MM, Monica F. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med. 2021 Mar;85:1-13. doi: 10.1016/j.ejim.2020.11.014. Epub 2020 Dec 2. PMID: 33279389. 4: Salloum A, Nasr D, Maalouf D. Dermatologic adverse reactions to proton-pump inhibitors: A synthetized review. J Cosmet Dermatol. 2021 Apr;20(4):1073-1079. doi: 10.1111/jocd.13763. Epub 2020 Oct 27. PMID: 33031621. 5: Tong S, Kaitu'u-Lino TJ, Hastie R, Brownfoot F, Cluver C, Hannan N. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. Am J Obstet Gynecol. 2020 Sep 16:S0002-9378(20)31071-1. doi: 10.1016/j.ajog.2020.09.014. Epub ahead of print. PMID: 32946849. 6: Scarpignato C, Hongo M, Wu JCY, Lottrup C, Lazarescu A, Stein E, Hunt RH. Pharmacologic treatment of GERD: Where we are now, and where are we going? Ann N Y Acad Sci. 2020 Dec;1482(1):193-212. doi: 10.1111/nyas.14473. Epub 2020 Sep 15. PMID: 32935346. 7: Ma'ayeh M, Costantine MM. Prevention of preeclampsia. Semin Fetal Neonatal Med. 2020 Oct;25(5):101123. doi: 10.1016/j.siny.2020.101123. Epub 2020 Jun 2. PMID: 32513597. 8: Ma'ayeh M, Rood KM, Kniss D, Costantine MM. Novel Interventions for the Prevention of Preeclampsia. Curr Hypertens Rep. 2020 Feb 12;22(2):17. doi: 10.1007/s11906-020-1026-8. PMID: 32052203. 9: Zhang HJ, Zhang XH, Liu J, Sun LN, Shen YW, Zhou C, Zhang HW, Xie LJ, Chen J, Liu Y, Wang YQ. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacol Res. 2020 Feb;152:104606. doi: 10.1016/j.phrs.2019.104606. Epub 2019 Dec 14. PMID: 31846760. 10: Ierardi E, Losurdo G, Fortezza RF, Principi M, Barone M, Leo AD. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J Gastroenterol. 2019 Sep 14;25(34):5097-5104. doi: 10.3748/wjg.v25.i34.5097. PMID: 31558859; PMCID: PMC6747288. 11: Eidenbenz D, Hirschel T, Schürmann G, Genné D. Fièvre médicamenteuse en médecine de premier recours liée aux médicaments les plus vendus en Suisse [Drug fever among Swiss' most sold drugs in primary care]. Rev Med Suisse. 2019 Aug 28;15(660):1516-1520. French. PMID: 31496177. 12: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Omeprazole. 2019 Apr 15. PMID: 31644080. 13: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Proton Pump Inhibitors. 2019 Apr 15. PMID: 31643228. 14: Sugimoto M, Yamaoka Y. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 2019 Jan 15;9:1560. doi: 10.3389/fphar.2018.01560. PMID: 30697158; PMCID: PMC6340927. 15: Novotny M, Klimova B, Valis M. PPI Long Term Use: Risk of Neurological Adverse Events? Front Neurol. 2019 Jan 8;9:1142. doi: 10.3389/fneur.2018.01142. PMID: 30671013; PMCID: PMC6331532. 16: Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2018 Feb;218(2S):S829-S840. doi: 10.1016/j.ajog.2017.11.565. Epub 2017 Dec 8. PMID: 29229321. 17: Rochoy M, Dubois S, Glantenet R, Gautier S, Lambert M. Le rebond d’acidité gastrique après arrêt d’un inhibiteur de la pompe à protons : revue narrative de littérature [Gastric acid rebound after a proton pump inhibitor: Narrative review of literature]. Therapie. 2018 May-Jun;73(3):237-246. French. doi: 10.1016/j.therap.2017.08.005. Epub 2017 Oct 26. PMID: 29195714. 18: Hillman L, Yadlapati R, Thuluvath AJ, Berendsen MA, Pandolfino JE. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus. 2017 Sep 1;30(9):1-15. doi: 10.1093/dote/dox055. PMID: 28859358; PMCID: PMC5788178. 19: Shamliyan TA, Middleton M, Borst C. Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs. Clin Ther. 2017 Feb;39(2):404-427.e36. doi: 10.1016/j.clinthera.2017.01.011. Epub 2017 Feb 9. PMID: 28189362. 20: Lacy SA, Miles DR, Nguyen LT. Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib. Clin Pharmacokinet. 2017 May;56(5):477-491. doi: 10.1007/s40262-016-0461-9. PMID: 27734291.